drugset
Drugs / SIZAVALEUCEL
last change Apr 2024 re-read 3 minutes ago

SIZAVALEUCEL

also known as MDR-101

Cell therapy

Developed for
transplant rejection

Trials 0

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Comparator or background therapy1 trial
Phase 3 NCT03363945 Comparator Mar 2018 → Apr 2024 transplant rejection Medeor Therapeutics, Inc. Completed No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2023-10-25 Medeor Therapeutics, Inc. Medeor Therapeutics to Present Interim Pivotal Data on MDR-101 Cell Therapy for Induction of Immune Tolerance and Elimination of Immunosuppressants Following Kidney Transplant in Late Breaker Oral Presentation at ASN Kidney Week 2023 medeortx.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as SIZAVALEUCEL ChEMBL registry synonym — accepted as the source's own label CHEMBL5095445 ↗
Known as MDR-101 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03363945 ↗
Modality Cell therapy “Medeor Therapeutics is developing a novel cell-based therapy” NCT03363945 ↗
Route Intravenous “A single dose will be administered via IV infusion post-kidney transplant.” NCT03363945 ↗